FDA Inspection 1288700 — Arevipharma GmbH
The FDA completed an inspection of Arevipharma GmbH on Jun 20, 2025 in Radebeul. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Jun 20, 2025
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Radebeul (Germany)
Additional Details
Mutual Recognition Agreement (MRA)